Progressive supranuclear palsy (PSP) is the second most common parkinsonian syndrome, characterized by a ‘diverse’ clinical phenotype. Although several different diagnostic guidelines have been proposed, the early and accurate diagnosis of PSP remains problematic and neuropathology is still considered the ‘gold standard’. In order to contribute to the better clinical characterization of PSP, we conducted a postmortem study in a cohort of 22 consecutive PSP brain donors and compared our results with those of previously published reports. Our results further demonstrate and expand the varied clinical picture of PSP. Furthermore, we report associations between older age at onset, early dementia, early falls and smoking with shorter PSP duration.

1.
Steele JC, Richardson JC, Olszewski J: Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964;10:333–359.
2.
Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, Lantos PL, McKee A, Tabaton M, Litvan I: Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994;44:2015–2019.
3.
Blin J, Baron JC, Dubois B, Pillon B, Cambon H, Cambier J, Agid Y: Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. Arch Neurol 1990;47:747–752.
4.
Golbe LI, Davis PH: Progressive Supranuclear Palsy. Baltimore, Williams and Wilkins, 1993.
5.
Lees AJ: The Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy); in Marsden CD, Fahn S (eds): Movement Disorders 2. London, Butterworth and Co, 1987, p 272–287.
6.
Litvan I, Agid Y, Jankovic J, Goetz C, Brandel JP, Lai EC, Wenning G, D’Olhaberriague L, Verny M, Chaudhuri KR, McKee A, Jellinger K, Bartko JJ, Mangone CA, Pearce RK: Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology 1996;46:922–930.
7.
Litvan I, Hauw JJ, Bartko JJ, Lantos PL, Daniel SE, Horoupian DS, McKee A, Dickson D, Bancher C, Tabaton M, Jellinger K, Anderson DW: Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 1996;55:97–105.
8.
Litvan I, Grimes DA, Lang AE, Jankovic J, McKee A, Verny M, Jellinger K, Chaudhuri KR, Pearce RK: Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration. J Neurol 1999;246(suppl 2):1–5.
9.
Litvan I, Campbell G, Mangone CA, Verny M, McKee A, Chaudhuri KR, Jellinger K, Pearce RK, D’Olhaberriague L: Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study. Brain 1997;120:65–74.
10.
Gearing M, Olson DA, Watts RL, Mirra SS: Progressive supranuclear palsy: neuropathologic and clinical heterogeneity. Neurology 1994;44:1015–1024.
11.
Verny M, Jellinger KA, Hauw JJ, Bancher C, Litvan I, Agid Y: Progressive supranuclear palsy: a clinicopathological study of 21 cases. Acta Neuropathol (Berl) 1996;91:427–431.
12.
Lopez OL, Litvan I, Catt KE, Stowe R, Klunk W, Kaufer DI, Becker JT, DeKosky ST: Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology 1999;53:1292–1299.
13.
Collins SJ, Ahlskog JE, Parisi JE, Maraganore DM: Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria. J Neurol Neurosurg Psychiatry 1995;58:167–173.
14.
Tolosa E, Valldeoriola F, Marti MJ: Clinical diagnosis and diagnostic criteria of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). J Neural Transm Suppl 1994;42:15–31.
15.
Osaki Y, Ben-Shlomo Y, Lees AJ, Daniel SE, Colosimo C, Wenning G, Quinn N: Accuracy of clinical diagnosis of progressive supranuclear palsy. Mov Disord 2004;19:181–189.
16.
Josephs KA, Dickson DW: Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. Mov Disord 2003;18:1018–1026.
17.
Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS: Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS- SPSP international workshop. Neurology 1996;47:1–9.
18.
Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
19.
Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L: The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 1991;41:479–486.
20.
American Psychiatric Association: Diagnostic and Statistical Manual for Psychiatric Disorders, ed 3, revised. Washington, American Psychiatric Association, 1987.
21.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 2000.
22.
Birdi S, Rajput AH, Fenton M, Donat JR, Rozdilsky B, Robinson C, Macaulay R, George D: Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord 2002;17:1255–1264.
23.
Golbe LI, Davis PH, Schoenberg BS, Duvoisin RC: Prevalence and natural history of progressive supranuclear palsy. Neurology 1988;38:1031–1034.
24.
Jackson JA, Jankovic J, Ford J: Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Ann Neurol 1983;13:273–278.
25.
Steele JC: Progressive supranuclear palsy. Brain 1972;95:693–704.
26.
Brusa A, Mancardi GL, Bugiani O: Progressive supranuclear palsy 1979: an overview. Ital J Neurol Sci 1980;1:205–222.
27.
Jellinger K, Riederer P, Tomonaga M: Progressive supranuclear palsy: clinico-pathological and biochemical studies. J Neural Transm Suppl 1980:111–128.
28.
Litvan I, Mangone CA, McKee A, Verny M, Parsa A, Jellinger K, D’Olhaberriague L, Chaudhuri KR, Pearce RK: Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 1996;60:615–620.
29.
De Bruin VM, Lees AJ: Subcortical neurofibrillary degeneration presenting as Steele-Richardson-Olszewski and other related syndromes: a review of 90 pathologically verified cases. Mov Disord 1994;9:381–389.
30.
Riley DE, Lang AE, Lewis A, Resch L, Ashby P, Hornykiewicz O, Black S: Cortical-basal ganglionic degeneration. Neurology 1990;40:1203–1212.
31.
Gibb WR, Luthert PJ, Marsden CD: Corticobasal degeneration. Brain 1989;112:1171–1192.
32.
Duvoisin RC, Golbe LI, Lepore FE: Progressive supranuclear palsy. Can J Neurol Sci 1987;14:547–554.
33.
Kristensen MO: Progressive supranuclear palsy – 20 years later. Acta Neurol Scand 1985;71:177–189.
34.
Quinn NP: Parkinson’s disease: clinical features; in Quinn NP (ed): Clinical Neurology-Parkinsonism. London, Bailliere Tindall, 1997, pp 1–13.
35.
Daniel SE, de Bruin VM, Lees AJ: The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): a reappraisal. Brain 1995;118:759–770.
36.
Nath U, Ben-Shlomo Y, Thomson RG, Lees AJ, Burn DJ: Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology 2003;60:910–916.
37.
Kida E, Barcikowska M, Niemczewska M: Immunohistochemical study of a case with progressive supranuclear palsy without ophthalmoplegia. Acta Neuropathol (Berl) 1992;83:328–332.
38.
Jankovic J: Progressive supranuclear palsy. Clinical and pharmacologic update. Neurol Clin 1984;2:473–486.
39.
Nieforth KA, Golbe LI: Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol 1993;16:338–346.
40.
Kompoliti K, Goetz CG, Litvan I, Jellinger K, Verny M: Pharmacological therapy in progressive supranuclear palsy. Arch Neurol 1998;55:1099–1102.
41.
Golbe LI: Progressive supranuclear palsy in the molecular age. Lancet 2000;356:870–871.
42.
Maher ER, Lees AJ: The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1986;36:1005–1008.
43.
Pfaffenbach DD, Layton DD, Jr., Kearns TP: Ocular manifestations in progressive supranuclear palsy. Am J Ophthalmol 1972;74:1179–1184.
44.
Davis PH, Bergeron C, McLachlan DR: Atypical presentation of progressive supranuclear palsy. Ann Neurol 1985;17:337–343.
45.
Perkin GD, Lees AJ, Stern GM, Kocen RS: Problems in the diagnosis of progressive supranuclear palsy. (Steele-Richardson-Olszewski syndrome). Can J Neurol Sci 1978;5:168–173.
46.
Chamberlain W: Restriction in upward gaze with advancing age. Am J Ophthalmol 1971;1:341–346.
47.
Chamberlain W: Restriction in upward gaze with advancing age. Trans Am Ophthalmol Soc 1970;68:234–244.
48.
Barclay CL, Lang AE: Dystonia in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1997;62:352–356.
49.
Litvan I, Sastry N, Sonies BC: Characterizing swallowing abnormalities in progressive supranuclear palsy. Neurology 1997;48:1654–1662.
50.
Janati A, Appel AR: Psychiatric aspects of progressive supranuclear palsy. J Nerv Ment Dis 1984;172:85–89.
51.
Golbe LI: Progressive supranuclear palsy. Curr Treat Options Neurol 2001;3:473–477.
52.
Fabbrini G, Barbanti P, Bonifati V, Colosimo C, Gasparini M, Vanacore N, Meco G: Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol Scand 2001;103:123–125.
53.
Scaravilli T, Pramstaller PP, Salerno A, Egarter-Vigl E, Giometto B, Vitaliani R, An SF, Revesz T: Neuronal loss in Onuf’s nucleus in three patients with progressive supranuclear palsy. Ann Neurol 2000;48:97–101.
54.
Holmberg B, Kallio M, Johnels B, Elam M: Cardiovascular reflex testing contributes to clinical evaluation and differential diagnosis of Parkinsonian syndromes. Mov Disord 2001;16:217–225.
55.
Santacruz P, Uttl B, Litvan I, Grafman J: Progressive supranuclear palsy: a survey of the disease course. Neurology 1998;50:1637–1647.
56.
Roos RA, Jongen JC, van der Velde EA: Clinical course of patients with idiopathic Parkinson’s disease. Mov Disord 1996;11:236–242.
57.
Esmonde T, Giles E, Gibson M, Hodges JR: Neuropsychological performance, disease severity, and depression in progressive supranuclear palsy. J Neurol 1996;243:638–643.
58.
Papapetropoulos S, Ellul J, Polychronopoulos P, Chroni E: A registry-based, case control investigation of Parkinson’s disease with and without cognitive impairment. Eur J Neurol 2004;11:347–351.
59.
Marder K, Leung D, Tang M, Bell K, Dooneief G, Cote L, Stern Y, Mayeux R: Are demented patients with Parkinson’s disease accurately reflected in prevalence surveys? A survival analysis. Neurology 1991;41:1240–1243.
60.
Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P: Smoking and lung cancer survival: the role of comorbidity and treatment. Chest 2004;125:27–37.
61.
Maraganore DM, Anderson DW, Bower JH, McDonnell SK, Rocca WA: Autopsy patterns for Parkinson’s disease and related disorders in Olmsted County, Minnesota. Neurology 1999;53:1342–1344.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.